Systemic lupus erythematosus (SLE) is a chronic inflammatory and autoimmune disease
characterised by multiple organ involvement and a large number of complications. SLE …

Systemic lupus erythematosus (SLE), the prototype of systemic autoimmune diseases is
characterized by extreme heterogeneity with a variable clinical course. Renal involvement …

This review summarizes traditional and emerging therapies for SLE. Evidence suggests that
the heterogeneity of SLE is a crucial aspect contributing to the failure of large clinical trials …

The dysregulation of multiple signaling pathways, including those through endosomal Toll-
like receptors (TLRs), Fc gamma receptors (FcγR), and antigen receptors in B cells (BCR) …

Introduction Systemic lupus erythematous is an autoimmune disease with diverse clinical
features and has its development associated with a complexity of genetic, hormonal and …

Objective To evaluate the safety, tolerability and efficacy of subcutaneous (SC) belimumab
in patients with systemic lupus erythematosus (SLE) beyond 1 year. Methods This was a 24 …

Belimumab is the only approved biological agent for the treatment of systemic lupus
erythematosus (SLE). It is a fully humanized IgG1γ monoclonal antibody directed against …

To evaluate the safety and tolerability of belimumab given for 24 months in patients
persistently positive for antiphospholipid antibodies (aPL) with clinical features attributable …

Recent advances in the understanding of immune dysregulation in autoimmune diseases
have enabled the development of new monoclonal antibody-based drugs called biologics …

What is already known about this subject?► BAFF/BLyS is a key cytokine in systemic lupus
erythematosus (SLe) and targeting BAFF by belimumab is used to treat patients with SLe.► …